VBI-2902

VBI-2902 is a protein subunit vaccine candidate developed by VBI Vaccines, a biopharmaceutical company based in Cambridge, Massachusetts. The vaccine is designed to prevent infection from the SARS-CoV-2 virus, which causes COVID-19.

Development

VBI-2902 is based on the company's enveloped virus-like particle (eVLP) platform, which mimics the structure of viruses to stimulate an immune response. The vaccine contains the SARS-CoV-2 spike protein, which the virus uses to enter human cells. By presenting this protein to the immune system, the vaccine aims to train it to recognize and attack the virus.

In preclinical studies, VBI-2902 demonstrated the ability to induce neutralizing antibodies against SARS-CoV-2. The vaccine is currently in Phase I/II clinical trials, where it is being tested for safety, tolerability, and immunogenicity in healthy adults.

Mechanism of Action

VBI-2902 works by stimulating the immune system to produce an immune response against the SARS-CoV-2 virus. The vaccine contains the spike protein of the virus, which is presented to the immune system. This triggers the production of antibodies that can recognize and neutralize the virus, preventing it from infecting cells and causing disease.

Clinical Trials

VBI-2902 is currently in Phase I/II clinical trials. The trials aim to evaluate the safety and efficacy of the vaccine in healthy adults. The primary endpoints of the trials include the assessment of adverse events, changes in vital signs, and the generation of an immune response against SARS-CoV-2.

Potential Impact

If successful, VBI-2902 could provide a new tool in the global fight against COVID-19. The vaccine's eVLP platform could potentially offer advantages over other vaccine technologies, such as increased stability and the ability to induce a broad and durable immune response.

See Also

• COVID-19 vaccine
• VBI Vaccines
• SARS-CoV-2
• Clinical trial
• Antibody

This article is a stub related to pharmacology. You can help WikiMD by expanding it!